Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
6 hedge funds and large institutions have $49.4K invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 474 closing their positions.
99% less funds holding
Funds holding: 485 → 6 (-479)
100% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 474
100% less funds holding in top 10
Funds holding in top 10: 80 → 0 (-80)
100% less capital invested
Capital invested by funds: $24.8B → $49.4K (-$24.8B)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| 1 |
BTI
Blue Trust Inc
Alpharetta,
Georgia
|
+$4.88K |
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.5B |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$1.8B |
| 3 |
BlackRock
New York
|
-$1.72B |
| 4 |
HI
HBK Investments
Dallas,
Texas
|
-$923M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$887M |
HZNP Hedge Fund Activity: Q4 2023 in Review
6 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q4 2023, worth a combined $49.4K — down 100% from $24.8B a quarter earlier.
Sellers outnumbered buyers: 474 funds closed out of HZNP and 2 opened new positions — a net loss of 472 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was Blue Trust Inc, opening a new position worth an estimated $4.88K. The largest seller was Vanguard Group, exiting entirely with an estimated $2.5B sold.
- 6 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q4 2023, down from 485 in Q3 2023.
- Funds reported $49.4K of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q4 2023, down 100% quarter-over-quarter.
- 2 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q4 2023 and 474 closed out, a net change of -472 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q4 2023 was Blue Trust Inc, an estimated $4.88K added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q4 2023 was Vanguard Group, an estimated $2.5B sold.
Based on aggregated 13F filings for Q4 2023.